Diagnostic Approach to Cephalosporin Allergy Testing (DACAT Trial)

Study Info
Started In 2025
Sites 7
Target Enrollment: 300 participants
About the study
DACAT is a multi-site clinical trial (NCT06406114) designed to improve the diagnosis of cephalosporin allergy. Because cephalosporins share similar chemical structures, many patients are unnecessarily labeled as allergic and restricted from using these important antibiotics. This study will enroll 300 participants across sites and use standardized double-blind skin testing and drug challenges to confirm or rule out suspected cephalosporin allergy and to develop an optimal, evidence-based diagnostic approach.
Learn more at DACAT – Massachusetts General Hospital and Study Details | NCT06406114 | Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing | ClinicalTrials.gov
Participating Sites
Team Members
PI
Site PI
Site PI
Site PI
Site PI
Site PI
Site PI